Ignite Creation Date:
2024-05-06 @ 1:39 AM
Last Modification Date:
2024-10-26 @ 11:07 AM
Study NCT ID:
NCT01861964
Status:
COMPLETED
Last Update Posted:
2016-11-28
First Post:
2013-05-08
Brief Title:
Effects of Xylooligosarcharide on Composition of the Human Colonic Microflora
Sponsor:
University of California Los Angeles
Organization:
University of California Los Angeles
Study Overview
Official Title:
Effects of Xylooligosarcharide on Composition of the Human Colonic Microflora
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
XOS
Brief Summary:
Human and animal studies demonstrate that xylooligosaccharides XOS are a highly efficacious prebiotic ingredient that delivers benefits at a minimum level of 14 gday d which is much lower than levels required by fructooligosaccharides FOS 5 gd or galactooligosaccharides GOS 8 gd XOS promotes gastrointestinal regularity and relieves diarrhea and constipation at 07 gd and 14 gd respectively Xylooligosaccharides may also reduce blood cholesterol and may improve glycemic control although more data from clinical trials are needed to confirm preliminary findings
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None